top of page

#EAU20 Virtual - Immunotherapy and beyond

EAU
7/18/20, 8:00 PM
Europe/Madrid GMT+2

Description

Immunotherapy and beyond

Thematic session 07

 

Sat 18 July

17:00 - 18:10

Location:Virtual room 1Chairs: S. Gillessen Sommer, Bellinzona (CH)

R.J. Van Soest, Rotterdam (NL)

 

Learning objectives

This session will provide an overview of the current challenges and obstacles in the treatment of urothelial cancer and renal cell carcinoma in view of recently approved agents and combinations including immunotherapy, targeted agents and combinations.

 

17:00 - 17:05

Introduction

17:05 - 17:50

Perioperative therapy for urothelial cancer

17:05 - 17:15

Chemotherapy remains standard of care

G. Niegisch, Düsseldorf (DE)

17:15 - 17:25

PD-1/PD-L1 Inhibitors are replacing perioperative chemotherapy

J.L. Boormans, Rotterdam (NL)

17:25 - 17:35

Should we sequence all urothelial cancer patients?

S. Shariat, Vienna (AT)

17:35 - 17:45

Novel urothelial cancer treatment beyond PD-1/PD-L1 inhibition

Y. Loriot, Villejuif (FR)

17:45 - 17:50

Discussion, questions and answers

17:50 - 18:15

Immunotherapy combinations for intermediate-poor risk mRCC

17:50 - 18:00

IO + TKI

A.S. Merseburger, Lübeck (DE)

18:00 - 18:10

IO + IO

M. Schmidinger, Vienna (AT)

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

S. Gillessen Sommer, R.J. Van Soest

Perioperative therapy for urothelial cancer

Inglês

Description

Speakers

G. Niegisch, J.L. Boormans, S. Shariat, Y. Loriot, A.S. Merseburger, M. Schmidinger

Speakers

Link to the Event

Banner to the Event

#EAU20 Virtual - Immunotherapy and beyond
Link to Event
Banner
Registro
bottom of page